Faeth Therapeutics
Clinical trials sponsored by Faeth Therapeutics, explained in plain language.
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control Recruiting nowThis study tests a new combination of drugs (sapanisertib and serabelisib, called PIKTOR) plus chemotherapy (paclitaxel) in people with advanced or recurrent endometrial cancer that has not been cured by prior treatments. About 40 participants will receive the drug combo, and a s…
Phase: PHASE2 • Sponsor: Faeth Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study is for people with a type of advanced breast cancer called HR+/HER2-. It tests two experimental drugs, sapanisertib and serabelisib, given with standard hormone therapy. The goal is to see if the combination is safe and can shrink tumors. About 32 participants will tak…
Phase: PHASE1, PHASE2 • Sponsor: Faeth Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:59 UTC